Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
Phase I Trial of Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectiv…
Metastatic Biliary Tract CancerMetastatic Biliary Tract Carcinoma
Washington University School of MedicineNCT07107750
Phase 1
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
Metastatic Biliary Tract Cancer
M.D. Anderson Cancer CenterNCT06548412